We seek to elucidate the factors that influence patients’ individual responses to drug substances, with the aim of optimising the treatment and safety for each patient.
The research helps ensure that drugs are administered at the correct dose, the optimal formulation and the right time to the right patient – producing the desired therapeutic effect with minimal side-effects and with the lowest possible use of resources.
Focus areas include:
- Conditions that involve pain and inflammation. The aim is to gain a better understanding of the individual effects of pain-relieving drugs through translational projects that involve animal models, human experimental and clinical pain models. Results from the pain models are consolidated by pharmacokinetic-pharmacodynamic (PK-PD) modelling.
- Treatment of particularly vulnerable groups of patients such as children, the chronically ill, and critically ill patients with organ failure.
- Clinical trial methodology – specifically the development of pragmatic trial design for partial replacement of traditional randomised design models.
- Methods for quality assurance and optimisation of drug handling procedures.
The work is conducted in close collaboration with researchers from a range of hospital departments, universities and pharmaceutical companies in Denmark and abroad.
- Molecular Disease Biology
The section studies molecular mechanisms which determine disease progression, especially in relation to cancer.
- The research involves a range of pharmaceutical activities – on scientific as well as practical levels – to ensure rational pharmacotherapy for both patients and society.
- The focus is on PK-PD modelling – the development of computer-based models to understand the processes involved in drug disposition and corresponding therapeutic effects as a function of time.
- Pharmacovigilance aims at at evaluating benefits/risks of drug therapy, and enable patients, healthcare professionals, and the pharmaceutical industry to improve drug use and prevent drug-related problems.